GLENN KEHRING: Open Payments
NPI 1144259367 · TOWSON, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,154 in 52 payments from 14 companies in 2025. Trend: 2023 $1,989 · 2024 $2,172 · 2025 $1,154
Food & beverage: $1,154
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 12 | $198 |
| Alnylam Pharmaceuticals Inc. | 6 | $181 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $146 |
| E.R. Squibb & Sons, L.L.C. | 6 | $110 |
| AstraZeneca Pharmaceuticals LP | 5 | $100 |
| Actelion Pharmaceuticals US, Inc. | 3 | $71 |
| Medtronic, Inc. | 3 | $69 |
| Edwards Lifesciences Corporation | 1 | $55 |
| Novartis Pharmaceuticals Corporation | 3 | $52 |
| Novo Nordisk Inc | 2 | $46 |
Products named: ELIQUIS, JARDIANCE, AMVUTTRA, VYNDAQEL, MICRA, FARXIGA, LEQVIO, OPSUMIT.
Industry payments across MD — which companies pay providers there.
